

Annexin Pharmaceuticals

Empowering the body to fight disease

PRESS RELEASE

STOCKHOLM, September 11, 2023

Annexin presents at Redeye Investor Forum in Gothenburg on September 14

Annexin Pharmaceuticals AB today announced that the company is participating at Redeye Investor Forum in Gothenburg on September 14, 2023, 18:00-20:00 CET. CEO Anders Haegerstrand will present the latest development of the company, including the recently presented promising signals of effect in the company's ongoing clinical RVO-study.

The presentation and moderated Q&A session is broadcasted live via Redeye's website www.redeye.se/events/, where registration for in-person attendance at Hotel Pigalle, Södra Hamngatan 2A in Gothenburg, also is available.

The presentation will also be available at Annexin's website afterwards at [Annexin Presentations](#).

For further information, please contact:

Anders Haegerstrand, CEO, tel 070 - 575 50 37

About Annexin Pharmaceuticals AB

Annexin Pharmaceuticals AB is a leading biotechnology company in the Annexin A5 field for the treatment of various diseases. The company's biological drug candidate ANXV – a human recombinant protein, Annexin A5 – is primarily intended for treatment of patients with injuries and inflammation of the blood vessels, but also for cancer. The company has an extensive patent portfolio for the treatment of diseases with Annexin A5 and for production of Annexin A5.

The Company is based in Stockholm, Sweden and listed on Nasdaq First North Growth Market, under the ticker ANNX. Redeye is the company's Certified Adviser.